Completed Studies

  1. Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial. 2005 – 2012
    1. Diener HC, Sacco RL, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW; Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) study group (Hsu CY). Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol 7(10):875-84, 2008. Erratum in: Lancet Neurol 7(11):985, 2008.
    2. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW; PRoFESS Study Group (Hsu CY). Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 359(12):1225-37, 2008.
    3. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, Vandermaelen C, Voigt T, Weber M, Yoon BW; PRoFESS Study Group (Hsu CY). Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 359(12):1238-51, 2008.
    4. Weber R, Weimar C, Wanke I, Möller-Hartmann C, Gizewski ER, Blatchford J, Hermansson K, Demchuk AM, Forsting M, Sacco RL, Saver JL, Warach S, Diener HC, Diehl A; PRoFESS Imaging Substudy Group.  Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy. Stroke. 2012 Feb;43(2):350-5.
    5. Weber R, Weimar C, Blatchford J, Hermansson K, Wanke I, Möller-Hartmann C, Gizewski ER, Forsting M, Demchuk AM, Sacco RL, Saver JL, Warach S, Diener HC, Diehl A; PRoFESS Imaging Substudy Group (HsuCY). Telmisartan on top of antihypertensive treatment does not prevent progression of cerebral white matter lesions in the prevention regimen for effectively avoiding second strokes (PRoFESS)  MRI substudy. Stroke. 2012 Sep;43(9):2336-42.
    6. Estol CJ, Bath PM, Gorelick PB, Cotton D, Martin RH; PRoFESS Publications Committee and PRoFESS Investigators (HsuCY). Differences in ischemic and hemorrhagic recurrence rates among raceethnic groups in the PRoFESS secondary stroke prevention trial. Int J Stroke. 2014 Mar 18. doi: 10.1111/ijs.12269. [Epub ahead of print]
  2. Study of Acute ViprinesTM for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancord (ViprinexTM) in Subjects Beginning Treatment within 6 Hours of the Onset of Acute Ischemic Stroke, 2005 – 2008.
  3. Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate 2005-2009.
    1. Connolly SJ, Ezekowitz, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139-51, 2009.
  4. Taiwan Stroke Registry, PAD-STROKE Survey (Aug 2008- Oct 2008)
  5. A paper based on Taiwan Stroke Registry was published in Circulation (122:1116-1123, 2010) with ethnically characteristic features in stroke patients in Taiwan that are distinctly different from the Caucasian stroke population. Prof. Ralph Sacco, President, American Heart Association/American Stroke Association, had the following remarks upon the publication of this paper: “Stroke is a bigger cause of death and actually more frequent in Asian countries, this (study) could have a tremendous impact on stroke outcomes in these nations.”
  6. Completed a PI-initiated multicenter stroke trial led by the TCTCS PI, Prof. Chung Y. Hsu, with all the TCTCS stroke centers in Taiwan (The SPAD Study). (2009-2013)
  7. Granulocyte Colony-Stimulating Factor (GCSF) as the trophic factor for activating stem cells and promoting angiogenesis. Circulation 110(13):1847-1854, 2004.
  8. Human olfactory ensheathing cells in promoting functional recovery after stroke.  J Clin Invest 118(1):133-148, 2008; 118(7):2482-2495, 2008.
  9. Novel therapeutic strategies based on autologous stem cells sorted from patients’ own peripheral blood for restoring function in disabled stroke patients have been advanced from bench to clinical trials with a world leading Phase II trial of stem cell therapy in stroke patients completed showing significant improvement in functional outcome in stroke patients with stable disability. Chen DC, Lin SZ, Fan JR, Lin CH, Lee W, Lin CC, Liu YJ, Tsai CH, Chen JC, Cho DY, Lee CC, Shyu WC. Intracerebral Implantation of Autologous Peripheral Blood Stem Cellsin Stroke Patients: a Randomized Phase II Study. Cell Transplant. 2014 Jan 29. [Epub ahead of print]
  10. Ma H, Parsons MW, Christensen S, Campbell C, Churilov L, Connelly A, Yan B, Bladin C, Phan T, Barber AP, Read S, Hankey GJ, Markus R, Wijeratne T,Grimley, Mahant N, Kleinig T, Sturm T, Lee A, Blacker D, Gerraty R, Krause M, Desmond PM, McBride SJ, Carey L, Howells DW, Hsu CY, Davis SM, and Donnan GA on behalf of the EXTEND investigators. A multicentre, randomized, double-blinded, placebo-controlled Phase III study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND). Int J Stroke 7(1): 74-80, 2012.